Darryl G. Cleary,Charles J. Reynolds,Miriam Michelle Berrey,Robert G. Hindes,William T. Symonds,Adrian S. Ray,Hongmei Mo,Christy M. Hebner,Reza Oliyai,Vahid Zia,Dimitrios Stefanidis,Rowchanak Pakdaman
申请号：
US14538736
公开号：
US20150150896A1
申请日:
2014.11.11
申请国别(地区):
US
年份:
2015
代理人:
摘要：
Disclosed herein are a composition and unit dosage form for the treatment of hepatitis C virus (HCV) infection comprising GS-7977 and at least one pharmaceutically acceptable excipient, as well as methods for making said composition and unit dosage form. Also disclosed herein is a method of treating a subject, preferably a human, infected with hepatitis C virus, said method comprising administering to the subject for a time period an effective amount of GS-7977 and an effective amount of ribavirin. In one aspect, the method comprises administering to the subject an interferon-free treatment regimen comprising an effective amount of GS-7977 and an effective amount of ribavirin. In a particular aspect, the method is sufficient to produce an undetectable amount of HCV RNA in the subject for at least 12 weeks after the end of the time period.
